Tianjin Development Holdings ( (HK:0882) ) just unveiled an update.

Tianjin Development Holdings has reported indicative first-half 2026 results from its indirect subsidiary Tianjin Lisheng Pharmaceutical, highlighting a sharp year-on-year decline in profitability. As an investment holding company with a significant stake in Lisheng Pharmaceutical, these results are relevant to its financial exposure to the Chinese pharmaceutical market.

Lisheng Pharmaceutical expects net profit attributable to shareholders for the period from 1 January to 30 June 2026 to fall by about 75.8% to 78.71% compared with the same period last year, with net profit after extraordinary items down roughly 31.9% to 41.5%. Basic earnings per share are projected to drop from RMB 1.11 to between RMB 0.23 and RMB 0.28, signaling a substantial earnings contraction that may weigh on shareholder returns and underscore operating pressures in its business, although the figures remain preliminary and unaudited.